MOHAMED ALHENNAWY: Open Payments
NPI 1417649377 · WAYNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,710 in 74 payments from 14 companies in 2025. Trend: 2023 $351 · 2024 $1,351 · 2025 $1,710
Food & beverage: $1,710
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $378 |
| ABBVIE INC. | 19 | $324 |
| Alkermes, Inc. | 11 | $297 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $207 |
| Neurocrine BioSciences, Inc. | 5 | $93 |
| Teva Pharmaceuticals USA, Inc. | 5 | $82 |
| Almatica Pharma LLC | 4 | $69 |
| Axsome Therapeutics, Inc. | 4 | $61 |
| Lundbeck LLC | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
Products named: VRAYLAR, REXULTI, CAPLYTA, LYBALVI, ABILIFY MAINTENA, INGREZZA, ARISTADA, LOREEV XR.
Industry payments across NJ — which companies pay providers there.
